Amgen's Humira Patent Challenge May Move To Court After PTO Board Declines Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Patent Trial and Appeal Board denies Amgen's inter partes review petitions seeking to knock out Humira formulation patents.